Late-breaking clinical trials presented at the 2005 and 2006 annual scientific meetings of
the ACC, AHA, and European Society of Cardiology, as well as selected other data, were …

The process of guideline development for management of patients with acute myocardial
infarction (AMI) has undergone substantial evolution since the inaugural publication entitled “…

Background— Age is an important determinant of outcomes for patients with acute coronary
syndromes (ACS); however, community practice reveals a disproportionately lower use of …

… Paul Wayne Armstrong Paul Wayne Armstrong … Modified with permission from
Armstrong et al. Circulation. 2003;107:2533–7. …

Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and …

Myocardial infarction is a major cause of death and disability worldwide. Coronary atherosclerosis
is a chronic disease with stable and unstable periods. During unstable periods with …

Background—Angiotensin-converting enzyme (ACE) inhibitors are generally prescribed by
physicians in doses lower than the large doses that have been shown to reduce morbidity …

Background The prognosis of patients hospitalized with acute myocardial ischemia is quite
variable. We examined the value of serum levels of cardiac troponin T, serum creatine kinase …

Background Nesiritide is approved in the United States for early relief of dyspnea in patients
with acute heart failure. Previous meta-analyses have raised questions regarding renal …

Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac
complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of …